Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces clinically significant weight loss (mean 6.2–12.9 kg) and glycemic control (HbA1c reduction -1.87 to -2.59%) in adults with type 2 diabetes, with efficacy increasing with dose up to 15 mg weekly.
Tirzepatide is a once-weekly injection for type 2 diabetes that helps lower blood sugar and lose weight. It starts at a low dose (2.5 mg) to minimize side effects like nausea, which usually improve over time. The dose can be increased every 4 weeks up to 15 mg based on tolerance and need. It is approved for adults with T2DM, especially those who are overweight or obese, and works by mimicking hormones that regulate blood sugar and appetite. Patients should follow dietary advice (smaller, low-fat meals) to manage GI side effects and monitor blood glucose, especially if taking other diabetes medications like insulin or sulfonylureas.
All five studies demonstrated that tirzepatide treatment achieved sustained statistically significant and clinically meaningful reductions from baseline in hemoglobin A1c (HbA1c) (– 1.87 to – 2.59%, – 20 to – 28 mmol/mol) and in body weight (– 6.2 to – 12.9 kg), compared to either placebo or active comparators (semaglutide 1 mg, insulin degludec and insulin glargine).
Why this rating
Based on phase 3 SURPASS clinical trial program involving multiple large-scale randomized controlled trials.
Source
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects
Luis Alberto Vázquez et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01587-6
More from this paper
- Tirzepatide enables a significant proportion of patients with type 2 diabetes to achieve normoglycemia (HbA1c < 5.7%) without clinically significant hypoglycemia, particularly when not combined with insulin or sulfonylureas.Strong
- Tirzepatide improves cardiovascular risk factors, including blood pressure, lipid profiles, and liver fat content, in patients with type 2 diabetes, without increasing the risk of major adverse cardiovascular events in high-risk patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →